Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology. Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
We are developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.
Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine to prevent the occurrence of ovarian cancer.
Be The First to Receive Breaking NewsSign Up Now